Biblio

80 resultats trouvés
Filtres: Auteur is Andre, Thierry  [Clear All Filters]
E
Zaanan A, Henriques J, Cohen R, Sefrioui D, Evrard C, de la Fouchardiere C, Lecomte T, Aparicio T, Svrcek M, Taieb J et al..  2021.  Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 113:djaa072.
Anota A, Vernerey D, Tournigand C, Chibaudel B, Samson B, Scheithauer W, Brusquant D, Andre T, de Gramont A, Bonnetain F.  2016.  Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: results of the GERCOR DREAM phase III trial. QUALITY OF LIFE RESEARCH. 25:112.
Anota A, Vernerey D, Tournigand C, Chibaudel B, Samson B, Scheithauer W, Brusquant D, Andre T, de Gramont A, Bonnetain F.  2016.  Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: results of the GERCOR DREAM phase III trial. QUALITY OF LIFE RESEARCH. 25:112.
F
Serdjebi C, Gagniere J, Desrame J, Fein F, Guimbaud R, Francois E, Andre T, Seitz J-F, Monterymard C, Arsene D et al..  2015.  FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients. PLOS ONE. 10:e0135907.
Carola C, Ghiringhelli F, Kim S, Andre T, Barlet J, Bengrine L, Marijon H, Garcia MLine, Borg C, Dainese L et al..  2018.  FOLFIRI3-aflibercept as second- or later-line therapy in patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY. 36
Carola C, Ghiringhelli F, Kim S, Andre T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol M-L, Borg C, Dainese L et al..  2018.  FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. WORLD JOURNAL OF CLINICAL ONCOLOGY. 9:110-118.
Chibaudel B, Andre T, Bachet JBaptiste, Auby D, Desrame J, Deplanque G, Lecaille C, Louvet C, Tournigand C, Lebrun-Ly V et al..  2015.  FOLFOX-aflibercept followed by maintenance therapy with fluoropyrimidine-aflibercept as first-line therapy in patients with metastatic colorectal cancer: A GERCOR single-arm phase II study (VELVET). JOURNAL OF CLINICAL ONCOLOGY. 33
Makhloufi S, Turpin A, Amrani Mel, Andre T, Truant S, Bachet J-B, Vernerey D, Hebbar M.  2020.  Fong's Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial. ANNALS OF SURGICAL ONCOLOGY. 27:877-885.
G
Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I et al..  2020.  Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. EUROPEAN JOURNAL OF CANCER. 130:63-71.
H
Buhard O, Lagrange A, Guilloux A, Colas C, Chouchene M, Wanherdrick K, Coulet F, Guillerm E, Dorard C, Marisa L et al..  2016.  HSP110 T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer. JOURNAL OF MEDICAL GENETICS. 53:377-384.
I
Jary M, Liu W-W, Yan D, Bai I, Muranyi A, Colle E, Brocheriou I, Turpin A, Radosevic-Robin N, Bourgoin P et al..  Submitted.  Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study. MOLECULAR ONCOLOGY.
Chibaudel B, Andre T, Samson B, Garcia-Larnicol M-L, Dauba J, Lledo G, Dupuis OJean Marie, Rinaldi Y, Mabro M, Aucoin N et al..  2018.  Impact of primary tumor sidedness on erlotinib efficacy in patients with metastatic colorectal cancer treated with bevacizumab maintenance: Results from the DREAM phase III trial.. JOURNAL OF CLINICAL ONCOLOGY. 36
Charton E, Bachet J-B, Chibaudel B, Validire P, Hammel P, Andre T, Louvet C, Anota A, Bonnetain F.  2016.  Impact on time until deterioration of health-related quality of life of a first-line therapy combining ABI-007 and gemcitabine or simplified LV5FU2 in patients with metastatic pancreatic cancer: results of clinical phase II trial AFUGEM. QUALITY OF LIFE RESEARCH. 25:59-60.
Charton E, Bachet J-B, Chibaudel B, Validire P, Hammel P, Andre T, Louvet C, Anota A, Bonnetain F.  2016.  Impact on time until deterioration of health-related quality of life of a first-line therapy combining ABI-007 and gemcitabine or simplified LV5FU2 in patients with metastatic pancreatic cancer: results of clinical phase II trial AFUGEM. QUALITY OF LIFE RESEARCH. 25:59-60.
Tournigand C, Chibaudel B, Samson B, Scheithauer W, Lledo G, Artru P, Viret F, Ramee J-F, Tubiana-Mathieu N, Dauba J et al..  2015.  Improving safety in first-line metastatic colorectal cancer (MCRC) therapy with bevacizumab: Modified FOLFOX7 versus XELOX2-Results of the induction phase of the GERCOR DREAM randomized phase III study.. JOURNAL OF CLINICAL ONCOLOGY. 33
L
Cohen R, Pudlarz T, Garcia-Larnicol M-L, Vernerey D, Dray X, Clavel L, Jary M, Piessen G, Zaanan A, Aparicio T et al..  2020.  Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment. BULLETIN DU CANCER. 107:438-446.
M
Pastor B, Andre T, Henriques J, Trouilloud I, Tournigand C, Jary M, Mazard T, Louvet C, Azan S, Bauer A et al..  2021.  Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment. MOLECULAR ONCOLOGY. 15:2401-2411.
N
Bachet J-B, Hammel P, Desrame J, Meurisse A, Chibaudel B, Andre T, Debourdeau P, Dauba J, Lecomte T, Seitz J-F et al..  2017.  Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. LANCET GASTROENTEROLOGY & HEPATOLOGY. 2:337-346.
Dubreuil O, Bachet JBaptiste, Hammel P, Desrame J, Meurisse A, Andre T, Debourdeau P, Dauba J, Lecomte T, Seitz JFrancois et al..  2017.  Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).. JOURNAL OF CLINICAL ONCOLOGY. 35
O
Sobrero AF, Andre T, Meyerhardt JA, Grothey A, Iveson T, Yoshino T, Sougklakos I, Meyers JP, Labianca R, Saunders MP et al..  2020.  Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Dur. JOURNAL OF CLINICAL ONCOLOGY. 38
Sobrero AF, Andre T, Meyerhardt JA, Grothey A, Iveson T, Yoshino T, Sougklakos I, Meyers JP, Labianca R, Saunders MP et al..  2020.  Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Dur. JOURNAL OF CLINICAL ONCOLOGY. 38
P
Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F et al..  2019.  Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. LANCET ONCOLOGY. 20:1263-1272.
Chibaudel B, Maindrault-Goebel F, Bachet J-B, Louvet C, Khalil A, Dupuis O, Hammel P, Garcia M-L, Bennamoun M, Brusquant D et al..  2016.  PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. CANCER MEDICINE. 5:676-683.
Chibaudel B, Maindrault-Goebel F, Andre T, Bachet JBaptiste, Louvet C, Khalil A, Dupuis OJean Marie, Hammel P, Garcia MLine, Bennamoun M et al..  2015.  PEPCOL: A randomized noncomparative phase II study of PEP02 (MM-398) or irinotecan in combination with leucovorin and 5-fluorouracil as second-line therapy in patients with unresectable metastatic colorectal cancer-A GERCOR Study.. JOURNAL OF CLINICAL ONCOLOGY. 33
Kim S, Meurisse A, Spehner L, Stouvenot M, Francois E, Buecher B, Andre T, Samalin E, Jary M, Nguyen T et al..  2020.  Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 12:1758835920975356.

Pages